WOW! @McdevittDamien Aspen Neuroscience colleagues announces $147.5M (!!!) in Series B financing to help fund clinical trials of the company’s 1st iPSC-derived autologous dopamine neuron replacement for #Parkinsons
Aspen Neuroscience announces $147.5M fina... - Cure Parkinson's
Aspen Neuroscience announces $147.5M financing to fund trials of the company’s 1st iPSC-derived autologous dopamine neuron replacement
Read more about...
1 Reply
•
Progress. Although still no date for a trial to actually start, never mind end
Not what you're looking for?
You may also like...
Aspen Neuroscience Trial - Autologous Neuronal Cell Replacement
-phase-12a-clinical-trial-of-autologous-neuronal-cell-replacement-therapy-for-parkinsons-disease-302
Aspen FINALLY Moving forward with Stem Cell Trials
Administration (FDA) has given Aspen Neuroscience clearance to launch a clinical trial of ANPD001,...
Covid 19 may infect dopamine neurons
article is in Neuroscience News and I guess this did not seem surprising to me...
Good News - Drugs to address chronic inflammation and PD - NodThera
NT-0796, and provides an update on the Company’s priority clinical development programme....
Big pharma never rest. A sad tale of corporate greed run amok.
consumers grasped until a series of baby-powder cases began to go to trial was that, for decades,...